Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the operation. Schellenberg Wittmer advised Santhera Pharmaceuticals Holding AG on the sale of its Raxone®/idebenone business for all...
Chiesi Farmaceutici S.p.A.’s Acquisition of Raxone/idebenone From Santhera Pharmaceuticals AG
Santhera Pharmaceuticals’ License Agreement With Catalyst Pharmaceuticals
Schellenberg Wittmer advises Santhera on license for North America for Vamorolone. Santhera Pharmaceuticals (SIX: SANN) has signed an exclusive license and collaboration agreement for vamorolone in...
Santhera Pharmaceuticals’ License Agreement With Sperogenix Therapeutics
chellenberg Wittmer advised Santhera Pharmaceuticals on the deal. Swiss Biotech Santhera has entered an exclusive licence agreement with China-based Sperogenix Therapeutics for the development of Vamorolone...